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Summary: A radioimmunoassay was established for the measurement of androst-4-en-17ß-ol-3,ll-dione
(11-oxotestosterone). Highly specific antiserum was raised in rabbits using androst-4-en-17ß-ol-3,ll-dione-
3-bovine serum albumin conjugate äs antigen. Cross reactivity with all steroids measured was less than 4%.
[l,2-3H2]androst-4-en-17ß-ol-3,ll-dione was synthesized from [l,2-2H2]pregn-4-ene-17a,21-diol-3,ll,20-
trione in a two Step reaction with [l,2-3H2]androst-4-ene-3,ll,17-trione äs intermediate. Purification of plas-
ma androst-4-en-17ß-ol-3,ll-dione was performed by thin-layer chromatography. The intra- and interassay
Variation was 7.6% and 8.9%, respectively. Furthermore, the radioimmunological procedure was checked
against the measurement of androst-4-en-17ß-ol-3,ll-dione in human plasma by gas chromatography/mass
spectrometry.
Mean plasma levels of androst-4-en-17ß-ol-3,ll-dione at 8 a. m. in healthy young subjects were 2.04 ± 0.63
nmol/1 (x ± SD) in males and 2.18 ± 0.89 nmol/1 in females. In both groups there was a marked decrease
during the night (p < 0.01), becoming 0.96 ± 0.33 and 0.96 ± 0.40 nmol/1, respectively, at 11 p.m.
Administration of human chorionic gonadotropin on 3 consecutive days did not influence the plasma concen-
trations of androst-4-en-17ß-ol-3,ll-dione, whereas both corticotropin (from 2.35 ± 1.12 to 1.65 ± 0.76
nmol/1; p < 0.02) and dexamethasone (from 2.40 ± 1.75 to 0.40 ± 0.16 nmol/1; p < 0.01) caused a significant
decrease of androst-4-en-17ß-ol-3,ll<lione. It is concluded that androst-4-en-17ß-ol-3,ll-dione appears to
be an adrenal androgen in men, the physiological role of which is of considerable interest.
Radioimmunoassay zur Messung von Androst-4-en-17ß-ol-3,ll-dion (l 1-Oxotestosteron) im Plasma des
Menschen
Zusammenfassung: Ein Radipimmunassay zur Messung von Androst-4-en-17ß-ol-3,ll-dion (11-Oxotesto-
steron) im menschlichen Plasma wurde aufgebaut. Dazu wurde von Kaninchen ein hochspezifisches Antise-
rum gegen in Position 3 an Rinderserumalbumin gekoppeltes Androst-4-en-17ß-ol-3,ll-dion gewonnen,
dessen Kreuzfeaktionen gegen alle gemessenen Steroide <4% war. [l,2-3H2]Androst-4-en-17ß-3,ll-dion
wurde ausgehend von [l,2-3H2]pregn-4-en*17a,21-diol-3,ll,20-trion in einer zweistufigen Reaktion über
[l,2-3H2]androst-4-en=3,lljl7-trion als Zwischenprodukt synthetisiert. Vor radioimmunologischer Messung
wurden die Plasmaextrakte durch Dünnschichtchromatographie gereinigt. Die Präzision der Messung von
Androst-4-en-17ß-ol-3,ll-dion betrug 7,6% und 8,9% (Intra- und Interassay-Variation). Außerdem wurde
das radioimmunologische Verfahren durch die Messung von Androst-4-en-17ß-ol-3,ll-dion im menschli-
chen Plasma mit Hilfe der Gaschromatographie/Massenspektrographie überprüft.
Die Konzentration von Androst-4-en-17ß-ol-3,ll-dion im Plasma junger gesunder Männer (n = 15) betrug
um 8 Uhr 2,04 ± 0,63 nmol/1 (x ± SD) und bei gesunden Frauen 2,18 ± 0,89 nmol/1 (n = 10). In beiden
Gruppen bestand eine deutliche tageszeitabhängigkeit (p < 0,01) mit Konzentrationen von 0,96 ± 0,33
(Männer) und 0,96"± 0,40 nmol/1 (Frauen) um 23.00 Uhr. Nach Applikation von HCG (3 x 5000 I.E.)
wurde keine Änderung der Konzentration von Androst-4-en-17ß-ol-3,ll-dion gemessen, während die Gabe
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von Corticotropin (0,25 mg i.v.; Abfall um 30%; p < 0,02) oder Dexamethason (3 mg oral am Vorabend;
Abfall um 83%; p < 0,01) eine signifikante Verminderung von Androst-4-en-17ß-ol-3,ll-dion im Plasma
bewirkten. Androst-4-en-17ß-ol-3,ll-dion ist ein bisher im Plasma des Menschen nicht gemessenes, adre-
nales Androgen, dessen Bedeutung unter physiologischen und pathophysiologischen Bedingungen durch wei-
tere Untersuchungen aufgeklärt werden muß.
Introduction
A vast number of androgens have been identified in
plasma and urine (1), and many of these have a func-
tional group at C-ll (2, 3). Since the Substrate speci-
ficity of the adrenal llß-hydroxylase (EC 1.14.15.4)
is not restricted to C-21-steroids (4, 5), the 11-hy-
droxy- and 11-oxo-androgens are believed to origi-
nale from the adrenal cortex (6). The physiological
role of these androgens is still unknown in man.
However, some Information is available about an-
drost-4-ene-llß,17ß-diol-3-one and androst-4-en-
17ß-ol-3,ll-dione (11-oxotestosterone), which have
been found in piscine plasma (7, 8, 9). Of these an-
drogens, androst-4-en-17ß-ol-3,11-dione appears to
be the main androgen in salmonides (10), whereas in
man it has not yet been measured.
Since the role of these androgens under physiologi-
cal and pathological conditions have not yet been in-
vestigated in men, we established a radioimmunoas-
say for the measurement of androst-4-en-17ß-ol-
3,11-dione in human plasma. For this purpose we
raised specific antibodies against androst-4-en-17ß-
ol-3,11-dione in rabbits and synthesized [1,2-
3H2]androst-4-en-17ß-ol-3,l 1-dione from [1,2·̂
3H2Jcortisone (for trivial names used see table 1).
Materials and Methods
Chemicals and equipment
Solvents and reagents of analytical grade were used without fur-
ther purification. Phosphate buffer (0.15 mol/l,.pH 7.0) contain-
ing l g/l gelatine served äs assay buffer. Charcoal (l g) and Dex-
tran T 70 (0.1 g) were suspended in 100 ml assay buffer. Bovine
serum albumin was obtained from MERCK. UV-spectra were
taken with a ZEISS-spectrometer (DM.4). Unisolve (ZINSSER,
Frankfurt, Germany) was used äs scintillation mixture. Tritium
was measured in a liquid scintillation spectrometer (PACKARD
Tricarb 460 C).
Nonradioactive and radioactive steroids were purchased from
SIGMA and NEW ENGLAND NUCLEAR, respectively.
Preparation of the androgen conjugate
The method used to prepare androst-4-en-17ß-ol-3,ll-dione-3-
bovine serum albumin was similar to that described by Erlanger et
al. (l 1). The conjugate was separated from the unconjügated ste-
roid by extensive dialysis against distilled water (301, 72 h). Un-
soluble particles were removed by centrifugation, and the super-
natant was lyophylized. Androst^-en-nß^ol^ll-dione-S-bo-
vine serum albumin conjugate formation was monitored by meas-
uring the spectra of bovine serum albumin between 200 and
300 n m before and after conjugation (12).
Immunization procedure (13)
Five female rabbits were immunized with 0.5 mg of äntigen emul-
sified in l ml phosphate buffer (pH 7.4) and 1.5 ml Freund's adju^
vant (DIFCO Lab.) by intradermal injections at multiple sites.
The first five injections were carried out every 14 days. Booster
injections were given every 6 weeks with the same amoünt of änti-
gen. The rabbits were bled at 14 day intervals after booster injec-
tions. The final dilution of antiserum used in the radioimmunoas-
say was 1:12000. Sera were stored at -35 °C.
Synthesis of labeled androst-4-enTl7ß-ol-3Jl-dione
Radioactive androst-4-en-17ß-ol-3,ll-dione is not available
commercially. [l,2-3H2]cortisone served äs Substrate for the syn-
thesis of [l,2-3H2]androst-4-en-17ß-ol-3,ll-dione using the
method of Appleby & Norymberski (14): A solution of [1,2-
3H2]cortisone (37 MBq = l mCi) in aqueous acetic acid (l + l by
vol.) was shaken with sodium bismuthate (l mg) in the dark for
l .5 h. Steroids were extracted with ethyl acetate. After evapora-
tion of the solvent thinMayer chromatography was perfofmed
(dichloromethane/ethanol 95 +V5 sby vol.). Transformation of
[l,2-3H2]cortisone to [l,2-3H2]andröst-4-ene-3,ll,17-trione was
88%. To this intermediate, dissolved in w-propanol (0.2ml), an
ice-cold solution of sodium borohydride (4 g) was added, and the
mixture allowed to stand for 10 h (4 °C). Reaction was stopped by
the addition of an aqueous solution of acetic acid (20 g/l). After
extraction, evaporation and thin-layer chromatography, the trans-
formation of [l,2-3H2]androst-4-ene-3,ll,17-triqne to [1,2-
3H2)androst-4-en-17ß-ol-3,ll-dione was found to be 47%. The
identity of the preparation with authentic androst-4-en-17ß-ol-
3,11-dione was checked by thin-layer chromatography in 2 differ-
ent solvent Systems (chloroform/methanol/HaÖ 90 + 10 + l by
vol. and dichloromethane/ethanol 95 4- 5 by vol.). In both Sys-
tems the labeled preparation used and the authentic androst-4-
en-17ß-ol-3,ll-dione migrated identically. Furthermore, only
one radioactive spot was detected using a BERTHOLD beta-
scanner. ;..:
Plasma extraction and chromatography
Plasma samples (1.0 ml) were mixed with labeled androst-4-en-
17ß-ol-3,11-dione (1500 counts/min) and allowed to equilibrate
for 15 min at room temperature. Steroids were extracted with di-
ethylether (5 ml). The solvent was removed by a gentle stream of
nitrogen and the residue was purified' by thin-layer chromatogra-
phy (MERCK silica 60 F 254; solvent System: cyclohexane/ethyl
«acetate 50 -H 50 by vol.). Androst-4-en-17ß-ol-3,ll-dione was
located from the position of chromatographed non-radioactive
androst-4-en-17ß-ol-3,l 1-dione (deteoted in UV), and by beta-
scanning of the spot.
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Radioimmunoassay
The methanolic eluates from thin-layer chromatography contain-
ing androst-4-en-17ß-ol-3,ll-dione were evaporated to dryness
under a stream of nitrogen and dissolved in methanol (0.5 ml).
Duplicates of 0.10ml were used for radioimmunoassay and a
0.20 ml sample was taken for the rneasurement of procedural loss
after evaporation of the solvent. To each tube (unknown samples
and Standards) [l,2-3H]androst-4-en-17ß-ol-3,ll-dione (about
8000 counts/min) in 0.05 ml and 0.20 ml of antiserum-buffer di-
lution were added. After incubation at 4 °C overnight, a charcoal
Suspension (0.5 ml) was added to each tube. The tubes were vor-
texed and after a 10 min incubation period at 4 °C they were cen-
trifuged at 1500g for 10 min. Aliquots of the supernatants were
placed in counting vials containing 10 ml scintillation fluid. The
procedure for the measurement of cortisol (15) and testosterone
(16) was described previously.
Experimental conditions
Androst-4-en-17ß-ol-3,ll-dione was measured in the plasma of
healthy male (n = 15) and female (n = 10) subjects (20—40 years
of age) at 8 a.m. and 11 p.m.
Corticotropin Stimulation of the adrenal gland was carried out by
i.v. injection of 0.25 mg corticotropin (Synacthen, GIB A, Basel/
Schweiz) in 8 healthy male volunteers. Blood was taken imme-
diately before and l h after Stimulation.
Dexamethasone (3 mg, orally) was applied for adrenal suppres-
sion at 11 p. m. to 8 healthy female subjects. Blood samples were
taken at 8 a.m. on the day of dexamethasone application and at 8
a. m. the day thereafter.
Testicular Stimulation was performed in 7 healthy male subjects äs
described previously (17). Qn the first and fourth day plasma was
collected at 8 a.m. and 7 p.m. and on the first, second and third
day 5.000 I.U. human chorionic gonadotropin were administered
i.m. at 7 p.m.
Statistics
Hormone concentrations were giveri äs mean ± Standard devia-
tion (x ± SD). Data were processed statistically using Studenfs t-
test or Wilcoxon's test.
Results
Rel iab i l i ty cri teria for the measurement of
androst-4-en-17ß-ol-3,17-dione in h u m a n
plasma
Specificity
The specificity of the antiserum was determined by
incubation of constant amounts of antiserum and la-
belled antigen with varying amounts of cross-react-
ing steroids (tab. 1). The highest cross-reaction was
3.4%.
Precision
The intra-assay coefficient of Variation was 7.6% (n
= 10), and the inter-assay coefficient of Variation
was 8.9% (n = 10).
Sensitivity
The sensitivity was estimated using the formula of
Abraham (18). The blank values for androst-4-en-
17ß-ol-3,ll-dione were 0.010 pmol/tube. Signifi-
cant differences from zero values were obtained
starting with 0.017 pmol androst-4-en-17ß-ol-
3,11-dione (fjg. i). After semi-logarithmic transfor-
mation the Standard curves showed linearity from
0.0332 to 3.32 pmol androst-4-en-17ß-ol-3,ll-di-
one.
Accuracy
The average recovery value of added [l,2-3H2]an-
drost-4-en-17ß-ol-3,ll-dione from 83 plasma sam-
ples was 86.1 ± 4.2%. All hormone concentrations
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Fig. 1. Mean Standard curve of androst-4-en-17ß-ol-3,ll-dione
(l 1-oxotestosterone) ( ± SD) obtained from 10 different
radioimmunoassays.
given were corrected for procedural loss using an in-
ternal Standard for each sample. One ml aliquots of
pooledmaleplasmawasheatedfor l hat 70°C,then
cleared of endogeneous steroids by charcoal absorp-
tion. To these plasma samples, 0,66, 1.32 or 2.31
pmol of non-radioactive androst-4-en-17ß-ol-3,ll-
dione were added. The samples were processed äs
usual. Comparison of the expected amounts deter-
mined in the described radioimmunoassay, gave a
correlation coefficient of r = 0.993.
Furthermore, accuracy (and precision) of the ra-
dioimmunological procedure was checked against
detection by gas chromatography/mass spectrometry
(L. Siekmann, Bonn; see acknowledgment). For gas
chromatography of the heptafluorobutyrate derivate
of androsM-en-lTß-ol^ll-dione a capillary co-
lumn (SE 30) was used. In a given sample of pool
plasma the substance was identified by the mass
peaks 600 and 490. The concentration measured by
radioimmunoassay was 0.795 nmol/1, and 0.773
nmol/1 when determined by the physico-chemical
method (difference 3%).
Plasma concefitrat ions of androst-4-en-
17ß-ol-3,17^dione
There was a marked diurnal Variation of both corti-
sol and androst-4-en-17ß-olr3,ll-dione when meas-
uring basal plasma concentrations (tab. 2). Concom-
itantly with cortisol, the concentration of androst-4-
en-17ß-ol-3,11-dione also decreased significantly (p
< 0.01) from 2.04 ± 0.63 in the males (2.18 ± 0.89
in female subjects) to 0.96 ± 0.53 (0.96 ± 0.40)
nmol/1 (decrease by 55%). Nö sex differences were
found in the plasma concentrations of androst-4-en-
17ß-ol-3,ll-dione at 8 a.m. or 11 p.m., respectively.
Tab. 2. Diurnal Variation of plasma cortisol and plasma androst-4-en-17ß-ol-3,ll-dione (nmol/I; ± SD) in healthy male/female
subjects, 20-40 years of age. Differences in sex were not statistically significant.
Males
(n = 15)
8a.m. 11 p.m. p
Females
(n = 10)
8 a. m. 11 p.m. P
Cortisol
Androst-4-en-17ß-ol-3,l 1-dione
344.7 ± 108.7 90.2 ± 53.0 <0.01
2.04 ± 0.63 0.96 ± 0.33 <0.01
302.2 ±92.2 67.6 ±47.4 <0.01
2.18 ± 0.89 0.96 ± 0.40 <0.01
To obtain ^g/I] multiply by 0.362 (cortisol) or 0.302 (androst-4-en-17ß-ol-3,ll-dione).
Tab. 3. Plasma cortisol and androst-4-en-17ß-ol-3,ll-dione
(nmol/1) before and after corticotropin Stimulation in 8
healthy males, 20-40 years of age. Blood was drawn at
8 a. m. and l h after i. v. injection of 0.25 mg cörticotrop-
Tab. 4. Plasma cortisol and androst-4-en-17ß-ol-3,ll-dione be-
fore and after adrenal suppression by dexamethasone in 8
healthy females subjects, 20-40 years of age. Blood was
drawn at 8 a. m. before and at 8 a. m. after dexametha-
sone application (at 11 p.m., orally).
Before After
Stimulation Stimulation
(B) (A) A/B p
Cortisol 222.4 ±80.9 651.0 ±96.3 2.94 <0.01









(B) (A) ' A/B p
262.4 ±93.8 11.0 ±8.3 0.042 <0.01
2.40 ± 1.75 0.40 ±0.16 0.167 <0.01
» r
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After corticotropin administration Cortisol increased
2.94 fold (tab. 3); in contrast to Cortisol, androst-4-
en-17ß-ol-3,l 1-dione decreased by 30% (p < 0.02)
(difference between values before and l h after cor-
ticotropin administration).
Dexamethasonc suppression of the adrcnal gland
caused a substantial decrease in Cortisol and androst-
4-en-17ß-ol-3,11-dione (p < 0.01) (tab.4). An-
drost-4-en-17ß-ol-3,ll-dione decreased by 83%
(from 2.40 ± 1,75 to 0.40 ±0.16 nmol/1).
Human chorionic gonadotropin Stimulation over a
period of 3 days in 7 male volunteers resulted in a 2-
fold increase in testosterone (tab. 5). Plasma an-
drost-4-en-17ß-o!-3,l 1-dione, however, remained
unaffected by elevated steroid sccrelion of the gon-
ads.
Tab. 5. Plasma testosterone and androst-4-en-17ß-ol-3,l 1-dionc
(nmol/1) beforc and after human chorionic gonadotropin
Stimulation in 7 healthy male subjects. 5.000 I.U. human
chorionic gonadotropin wcre givcn i. m. on 3 consecutivc
days at 7 p.m. Blood was drawn at 8 a.m. and at 7 p.m.
on the first and the fourth day. Data rcprcscnt the mcan


















To obtain [ng/l] multiply by 0.288 (testosterone) or 0.302 (an-
drost-4-en-17ß-ol-3,l 1-dione).
Discussion
The development of a radioimmunoaßsay for the de-
termination of androst-4-en-17ß-ol-3,11-dione is
described. The antiserum was of high specificity
(tab. 1). The maximal cross-reaction with other ste-
roids was smaller than 4%. Therefore the assay
might have been used without chromatographical
Separation of other plasma steroids. The fact, how-
ever, that this particular androgen has not been
quantified in human peripheral blood so far, makes
it necessary to minimize any possible unspecific ef-
fects. For this reason we used thin-Iayer chromato-
graphy before radioimmunoassay. Furthermore, for
the same reason, prccision and accuracy of the meth-
od were validated by a different physico-chemical
procedure. Using gas chromatography/mass spec-
trometry, androst-4-en-17ß-ol-3,11-dione was mea-
sured in human plasma. Moreover, both indcpend-
ent methods gave almost identical results when
measuring plasma concentrations of a pool plasma.
The purity of the [l,2-3H2]androst-4-en-17ß-ol-
3,11-dione preparation was checked in two thin lay-
cr chromatography-systems. In both Systems [1,2-
3H2]androst-4-en-17ß-ol-3,l 1-dione migratcd iden-
tically with authentic unlabelcd androst-4-en-17ß-
ol-3J 1-dione.
It was dernonstrated that androst-4-en-I7ß-ol-3, l 1-
dione is present in the plasma of male subjects in
considerable amounts (about 2 nmol/1). This ränge
of plasma conccntration is comparable with that of
androst-4-ene-3,17-dione in men (19) and is even
higher than that of 5ct-androstan-17ß~ol-3-one. In
females androst-4-en-17ß-ol-3,17-dione even ex-
ceeds the known average testosterone concentration
(20). However, in contrasl to testosterone, no sex
differences could be found for androst-4-en-17ß-ol-
3,11-dione.
Our data demonstrate that the androst-4-en-17ß-ol-
3,11-dione concentration is substantially higher in
the morning (tab. 2) than in the evening, suggesting
a circadian rhythm of the type already described for
cortisol plasma levels. Furthermore, it was shown
that dexamethasone application lowered androst-4-
en-17ß-ol-3,ll-dione levels significantly, which was
again paralleled by a fall of cortisol concentration.
Unexpectedly, corticotropin application resulted in a
decrease in androst-4-en~17ß-ol-3,11-dione plasma
concentrations. This phenomenon has not yet been
described. Sharma et al. (21), however, were able to
show that adrenal and gonadal androgens (andro-
stenedione, androst-5-en-3ß-ol-17-one, testoste-
rone) are effective competitive inhibitors in the con-
version of 11-deoxycorticosterone (pregn-4-en-21-
ol-3,20-dione) to · corticosteronc (pregn-4-ene-
llß,21-diol-3,20-dione) in bovine adrenals; in-vivo
androgen Inhibition of 11 ß-hydroxylase (EC
1.14.15.4) appears to be of minor importance. This
is demonstrated by increased cortisol after cortico-
tropin and the unaffected plasma values of androst-
4-en- 17ß-ol-3,11 -dione after human chorionic go-
nadotropin Stimulation.
As demonstrated by our studies with human chori-
onic gonadotropin Stimulation on the Leydig cclls,
plasma androst-4-en-17ß-ol-3,11-dione appears to
depend cxclusively on adrenal synthesis in male sub-
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jects, thus making this steroid a specific marker of
adrenal function.
Further studies will show whether or not androst-4-
en-17ß-ol-3,ll-dione plays a (substantial) role dur-
ing maturation and ageing, äs well äs in pathological
conditions of adrenal function.
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